Plain-English translation of NCT06264388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and DB107-Flucytosine (FC) — a two-part combination treatment — can shrink high-grade brain tumors (glioblastoma or anaplastic astrocytoma) that have come back after previous treatment. The first part is a special virus that gets placed directly into the tumor during surgery. The second part is a pill you take at home for one week every six weeks over up to a year. Researchers want to see if this combination can slow down or stop tumor growth better than other options.
High-grade brain tumors often come back even after surgery, radiation, and chemotherapy, and current treatments don't work well for everyone. This trial exists to test whether this new two-part approach—using a virus to attack tumor cells combined with an oral medication—might be more effective at controlling recurring tumors and extending the time before the disease progresses.
You likely qualify if…
You likely don't qualify if…
You would undergo surgery to have your tumor removed or biopsied, during which the special virus treatment () is placed directly into the tumor. About six weeks after surgery, you begin taking oral medication () at home for 7 days—you repeat this 7-day cycle every 6 weeks for up to 12 months. Throughout this time, you'll have regular blood tests and MRI scans to monitor how the tumor is responding. After you finish treatment, you'll continue having follow-up visits and scans for at least 5 years.
AI-generated summary from trial data · Aug 18, 2026 · Not medical advice
United States